This guide is currently available in English. A Spanish version is in progress.
Sourcing Exosomes in New Mexico
Licensed New Mexico practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. New Mexico buyers need their own professional license and NPI; the wholesale drug distributor license is the supplier’s obligation, not the purchaser’s.
New Mexico granted certified nurse practitioners independent practice and prescriptive authority in 1993, earlier than almost any state, so NP-led practices are an established structure here rather than a recent development. The state also works differently at the cash register: it levies a gross receipts tax on the seller rather than a conventional sales tax, which changes what resale documentation looks like.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Nuevo México? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | None |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | No |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material. Compounded preparations are not available in this state at this time |
| Last reviewed | 16 October 2026 |
Ordering from Nuevo México
ExaVeyra ships to licensed practices in all 50 states, New Mexico included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active New Mexico professional license in good standing, verifiable through the New Mexico Medical Board, the Board of Nursing, or the RLD license verification service.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- A New Mexico nontaxable transaction certificate (NTTC) from the Taxation and Revenue Department if the practice is purchasing for resale, since New Mexico levies a gross receipts tax on sellers rather than a conventional sales tax.
How the state permits wholesale distribution
New Mexico licenses wholesale drug distribution through the Board of Pharmacy, within the Regulation and Licensing Department, under 16.19.8 NMAC: every wholesale drug distributor, wherever located, who engages in wholesale distribution into, out of, or within the state must be licensed by the board. The part also reaches third-party logistics providers and repackagers and tracks the federal Drug Supply Chain Security Act, and the regime covers prescription drugs. The license sits with the distributor, not with the purchasing practice.
NMSA 1978, §§ 61-11-6, 61-11-14; 16.19.8 NMAC · New Mexico Regulation and Licensing Department, Board of Pharmacy
Nuevo México regenerative-medicine law
Nuevo México has not enacted a statute specific to stem cell or regenerative therapies. Practice in this area is governed by the state's general medical practice and professional licensing rules, alongside federal law.
No New Mexico statute addresses unapproved regenerative therapy, so federal law is the only layer. The legislature has been asked repeatedly: Biomedical Research Act bills to permit research on limited categories of human embryonic stem cells were introduced in 2007, 2008, 2009, and 2013, and every one failed, SB 77 of 2009 on the House floor by a vote of 30 to 38 and SB 313 of 2013 by indefinite postponement. Those were research bills in any case, not practice authorizations. Practice in this area is governed by the Medical Practice Act, the Nursing Practice Act, and the boards that administer them, alongside federal law.
How this applies to exosomes
New Mexico has no stem cell authorization law like Florida, Texas, or Georgia, no disclosure law like California, and no documentation statute like Tennessee. The Biomedical Research Act bills that appear in its legislative history were embryonic stem cell research measures that never passed, and none of them concerned clinical administration. There is therefore no New Mexico definition to read exosomes into or out of, and exosomes are acellular extracellular vesicles rather than stem cells in any case. Exosome products in New Mexico are governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Nuevo México practice
Because certified nurse practitioners hold independent authority, New Mexico supports two workable structures: a CNP-led practice that evaluates, orders, and prescribes within its own scope, and a physician-led practice that delegates conventionally. Physicians and PAs verify through the New Mexico Medical Board, nurses through the Board of Nursing, and the Board of Pharmacy sits inside the Regulation and Licensing Department, so verification spans three portals rather than one.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the New Mexico Medical Board under the Medical Practice Act may perform medical acts within their scope and are the source of supervision or collaboration for physician assistants. |
| NP / APRN | Certified nurse practitioners practice independently in New Mexico and have since 1993, under what is now NMSA 1978, section 61-3-23.2, regulated solely by the Board of Nursing. A CNP who has met the board’s requirements holds prescriptive authority, including controlled substances, under the board’s rules and formulary provisions, with no physician collaboration requirement. |
| PA | Physician assistants practice under physician supervision by default. Under 16.10.15 NMAC, a PA practicing primary care with three years of supervised clinical practice may instead work in collaboration with a physician, where the collaborating physician does not assume legal responsibility and need not be physically present. Specialty care PAs remain supervised. |
| RN | Registered nurses licensed by the Board of Nursing may perform delegated treatments within their scope and under an order from a provider with authority to issue one. An RN does not evaluate the patient or set the treatment plan. |
Good faith examination
New Mexico expects a patient evaluation by a provider with authority to conduct it, and an order, before a delegated treatment is administered. A certified nurse practitioner can be that provider. Confirm current expectations with the New Mexico Medical Board and the Board of Nursing, since this area is governed by board rule and interpretation rather than a single statute.
Ownership and clinic licensing
New Mexico has historically taken a permissive position on the corporate practice of medicine: a 1987 Attorney General opinion concluded that a corporation organized and controlled by non-physicians may provide medical services through employed physicians, so long as there is no lay control of medical judgment. The legislature considered codifying a Corporate Practice of Medicine Act in 2025, SB 450, and the bill died in committee, so the permissive posture stands. Lay control of clinical decisions remains off limits, and ownership structure is still worth a conversation with New Mexico counsel.
Cold chain into Nuevo México
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Nuevo México order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Albuquerque | Bernalillo | Largest New Mexico market, with most of the state’s aesthetic coverage. |
| Santa Fe | Santa Fe | Capital market with wellness, aesthetic, and concierge practices. |
| Rio Rancho | Sandoval | Served alongside Albuquerque on the same metro lane. |
| Las Cruces | Doña Ana | Southern market serving the Mesilla Valley and the El Paso border corridor. |
| Farmington | San Juan | Four Corners regional hub for northwestern New Mexico. |
- New Mexico orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Each shipment arrives with the manufacturer’s handling instructions and the lot-specific Certificate of Analysis.
Practice types we supply in Nuevo México
Nuevo México licensing and verification
New Mexico Medical Board
Licenses physicians and physician assistants under the Medical Practice Act.
New Mexico Board of Nursing
Sole regulator of certified nurse practitioners, who practice independently.
New Mexico Board of Pharmacy (RLD)
Licenses the wholesale drug distributors that ship into New Mexico.
New Mexico Taxation and Revenue Department
Gross receipts tax registration and nontaxable transaction certificates.
Nuevo México sourcing questions
- Does New Mexico have a stem cell law?
- No. Biomedical Research Act bills to permit research on limited categories of human embryonic stem cells were introduced in 2007, 2008, 2009, and 2013, and all of them failed; they were research measures, not practice laws, in any case. With no state statute on the books, exosome products in New Mexico are governed by federal law, under which no exosome product is FDA approved for administration to humans.
- Are exosomes FDA approved?
- No exosome product has been approved by the FDA for administration to humans, in New Mexico or anywhere else, and the FDA has issued a public safety notification on exosome products. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot documentation on every vial.
- Can a nurse practitioner run a practice in New Mexico without a physician?
- Yes, and this has been true since 1993. Certified nurse practitioners practice independently under NMSA 1978, section 61-3-23.2, regulated solely by the Board of Nursing, with prescriptive authority including controlled substances under the board’s rules. A CNP-led practice evaluates, orders, and prescribes within its own scope.
- How do physician assistants practice in New Mexico?
- Supervision is the default: the supervising physician exercises oversight and assumes legal responsibility, though physical presence is not required. Under 16.10.15 NMAC, a PA practicing primary care with three years of supervised clinical practice may move to a collaboration model, where the collaborating physician does not assume legal responsibility. Specialty care PAs remain supervised.
- Does my New Mexico clinic need a wholesale drug distributor license to buy exosomes?
- No. Under 16.19.8 NMAC the license is held by the wholesale distributor shipping into New Mexico, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- How does New Mexico tax practice purchases?
- New Mexico levies a gross receipts tax on the seller rather than a conventional sales tax on the buyer, and sellers commonly pass it through on the invoice. A practice purchasing for resale documents the resale with a nontaxable transaction certificate from the Taxation and Revenue Department rather than the resale certificate other states use.
- How long does cold-chain shipping take to New Mexico?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- 16.19.8 NMAC, wholesale distributors, third-party logistics providers, repackagers (accessed 16 October 2026)
- 16.10.15 NMAC, physician assistants (accessed 16 October 2026)
- New Mexico Board of Pharmacy (RLD) (accessed 16 October 2026)
- New Mexico Board of Nursing (accessed 16 October 2026)
- New Mexico Medical Board (accessed 16 October 2026)
- New Mexico Legislature, SB 313 (2013), Biomedical Research Act (died) (accessed 16 October 2026)
- New Mexico Taxation and Revenue Department (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018. doi:10.1080/20013078.2018.1535750 PMID:30637094Clinical guidelinesupports: The landmark characterization standard for extracellular vesicles, the baseline this page assumes when it describes what a defensible exosome COA and lot documentation package reports.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: The current revision of the MISEV standard, supporting this page’s point that EV characterization expectations come from the field’s consensus guidelines rather than from any New Mexico statute.
- Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. Journal of Extracellular Vesicles, 2015. doi:10.3402/jev.v4.30087 PMID:26725829Consensus statementsupports: The ISEV position on manufacturing, safety, and regulatory expectations for EV-based products, the context for this page’s statement that no exosome product holds FDA approval.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.